Press Release
AMB302, FGFR3-Targeting ADC Selected for KDDF Program
2023.12.13
- - AimedBio’s FGFR3-targeting ADC candidate AMB302 has been selected for the Korean Drug Development Fund (KDDF) program, receiving funding over the next two years to support preclinical development.
- - AMB302 is being developed for the treatment of bladder cancer and glioblastoma.
- - Preclinical studies have demonstrated strong efficacy and a favorable safety profile.
- - The company plans to submit an FDA IND application in the first half of 2024.